[go: up one dir, main page]

MX2008013039A - Metodo para aliviar la queratoconjuntivitis sicca. - Google Patents

Metodo para aliviar la queratoconjuntivitis sicca.

Info

Publication number
MX2008013039A
MX2008013039A MX2008013039A MX2008013039A MX2008013039A MX 2008013039 A MX2008013039 A MX 2008013039A MX 2008013039 A MX2008013039 A MX 2008013039A MX 2008013039 A MX2008013039 A MX 2008013039A MX 2008013039 A MX2008013039 A MX 2008013039A
Authority
MX
Mexico
Prior art keywords
alleviating
keratoconjunctivitis sicca
tear production
compound
topical
Prior art date
Application number
MX2008013039A
Other languages
English (en)
Inventor
Joel Bernstein
Original Assignee
Winston Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winston Lab Inc filed Critical Winston Lab Inc
Publication of MX2008013039A publication Critical patent/MX2008013039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención describe un método mejorado para aumentar la producción de lágrimas mediante la administración intranasalmente de una cantidad terapéuticamente efectiva de un compuesto capsaicinoide a pacientes con una producción deficientes de lágrimas. La incorporación opcional en la formulación intranasal de un corticosteroide tópico o compuesto anestésico tópico se usa para reducir la picazón y quemazón nasal transiente que a menudo pueden acompañar la administración intranasal de los capsaicinoides.
MX2008013039A 2007-10-05 2007-10-08 Metodo para aliviar la queratoconjuntivitis sicca. MX2008013039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/868,286 US20090093446A1 (en) 2007-10-05 2007-10-05 Method for alleviating keratoconjunctivitis sicca
PCT/US2007/080707 WO2009045224A1 (en) 2007-10-05 2007-10-08 Method for alleviating keratoconjunctivitis sicca

Publications (1)

Publication Number Publication Date
MX2008013039A true MX2008013039A (es) 2009-06-05

Family

ID=40523784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013039A MX2008013039A (es) 2007-10-05 2007-10-08 Metodo para aliviar la queratoconjuntivitis sicca.

Country Status (13)

Country Link
US (1) US20090093446A1 (es)
EP (1) EP2094256A4 (es)
JP (1) JP2009545634A (es)
KR (1) KR20090080017A (es)
CN (1) CN101616663A (es)
AR (1) AR068669A1 (es)
AU (1) AU2007349197A1 (es)
BR (1) BRPI0710595A2 (es)
CA (1) CA2644733A1 (es)
IL (1) IL198657A0 (es)
MX (1) MX2008013039A (es)
NZ (1) NZ571467A (es)
WO (1) WO2009045224A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166925B2 (en) 2018-08-23 2021-11-09 Elorac, Inc. Method for alleviating keratoconjunctivitis sicca

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019203A2 (en) * 2010-08-03 2012-02-09 Dynova Laboratories, Inc. Therapeutic agent for intranasal administration and method of making and using same
ES2739490T3 (es) 2010-11-16 2020-01-31 Univ Leland Stanford Junior Sistemas para el tratamiento del ojo seco
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
CA2840932C (en) * 2011-07-07 2020-01-21 Eva MILLQVIST Cough reducing product
WO2014031964A1 (en) * 2012-08-24 2014-02-27 Vr1, Inc. Composition for the treatment of migraine headaches
CN105307718B (zh) 2013-04-19 2018-05-11 奥库利维公司 鼻刺激装置和方法
CN107106542B (zh) 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
EP3721938A1 (en) * 2014-10-22 2020-10-14 Oculeve, Inc. Stimulation devices and methods for treating dry eye
NZ746468A (en) 2016-04-07 2023-06-30 Oyster Point Pharma Inc Methods of treating ocular conditions
AU2017260237A1 (en) 2016-05-02 2018-11-22 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
WO2020014217A1 (en) * 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
CN112384208A (zh) * 2018-08-23 2021-02-19 埃洛拉克有限公司 用于缓解干燥性角膜结膜炎的方法和组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134166A (en) * 1988-12-02 1992-07-28 Genderm Corporation Method for treating nasal disorders and headaches
CA2017383A1 (en) * 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
US5063060A (en) * 1989-12-19 1991-11-05 Cisco Limited Partnership Compositions and method for treating painful, inflammatory or allergic disorders
DE59408028D1 (de) * 1993-09-30 1999-05-06 Medichemie Ag Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie
CH690023A5 (de) * 1996-02-02 2000-03-31 Medichemie Ag Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut.
ZA99733B (en) * 1998-01-30 1999-08-02 R Tech Ueno Ltd Ophthalmic composition.
JP4653516B2 (ja) * 2004-02-27 2011-03-16 扶桑薬品工業株式会社 涙液分泌促進ペプチドおよびその組成物
DE102004063363A1 (de) * 2004-06-28 2006-01-19 Weber, Erhard, Dr. Capsaicin-haltige Arzneien zur Behandlung von Bronchial-Infekten und Allergien
US20060148903A1 (en) * 2004-11-24 2006-07-06 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166925B2 (en) 2018-08-23 2021-11-09 Elorac, Inc. Method for alleviating keratoconjunctivitis sicca
US11478439B2 (en) 2018-08-23 2022-10-25 Elorac, Inc. Method for alleviating keratoconjunctivitis sicca

Also Published As

Publication number Publication date
EP2094256A1 (en) 2009-09-02
KR20090080017A (ko) 2009-07-23
CN101616663A (zh) 2009-12-30
AR068669A1 (es) 2009-11-25
IL198657A0 (en) 2010-02-17
US20090093446A1 (en) 2009-04-09
AU2007349197A1 (en) 2009-04-23
CA2644733A1 (en) 2009-04-05
WO2009045224A1 (en) 2009-04-09
JP2009545634A (ja) 2009-12-24
NZ571467A (en) 2009-03-31
EP2094256A4 (en) 2009-11-11
BRPI0710595A2 (pt) 2011-08-16

Similar Documents

Publication Publication Date Title
MX2008013039A (es) Metodo para aliviar la queratoconjuntivitis sicca.
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
MX2010006284A (es) Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal.
MX2011011126A (es) Composiciones y metodos para tratar quemaduras.
WO2012116290A3 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
MY160074A (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
MX2010001236A (es) Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1).
WO2011141929A3 (en) Aqueous pharmaceutical compositions of fluticasone and olopatadine
WO2012027693A3 (en) Pharmaceutical compositions comprising poh derivatives
NZ599136A (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
MX2012013212A (es) Forma farmaceutica oral resistente al alcohol.
EP4620525A3 (en) Methods and compositions for treatment of pulmonary hypertension and other lung disorders
WO2012007159A3 (en) Novel gastro-retentive dosage forms
WO2007134241A3 (en) Nasal delivery of therapeutic agents using tight junction agonists
RU2011101151A (ru) Интраназальные композиции, содержащие деконгестант и кортикостероид
MX2015012072A (es) Esteres de glicopirrolato anticolinergico para el tratamiento de hiperhidrosis.
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
NZ594210A (en) Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
MX372770B (es) Composiciones para comprimidos bucodispersables que contienen corticosteroides para esofagitis eosinofílica.
NZ597488A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
WO2012135812A3 (en) Treatment for dermatological pathologies
WO2009015485A8 (en) Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
MX2015017879A (es) Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal